MibeTec US, an independent member of the Dermapharm Group, distributes high-quality medical devices made in Germany.
COMPETENCE IN DERMATOLOGY - OUR ORIGIN —
The drug specialists in the field of dermatology with our own production, development and independent distribution.
Homogeneous, dynamic development and the principle of sustainability are the keys to Dermapharm's success - today and in the future.
MibeTec US, Inc. is part of mibeTec GmbH, Germany
mibeTec GmbH is a high-quality medical device manufacturer that is actively developing and manufacturing superior products in state-of-the-art medical device laboratories and factories in Germany. The products of mibeTec have been marketed for over 20 years in Germany and today are available in 25 countries worldwide.
In 2018, MibeTec US was established in preparation for the launch of the company’s first US product, bite away®. bite away is a medical device leveraging patented* heat safety technology, and designed to treat insect bites and stings, with consumer sales beginning in autumn of 2019.
mibeTec Germany is an independent member of the Dermapharm Group, a wholly owned subsidiary of Dermapharm Holding SE. Since 1991 Dermapharm has been a leading manufacturer of pharmaceuticals, food supplements, cosmetics and medical devices for selected markets in Germany. Today, Dermapharm remains a family-run, German-based company with headquarters located in the historic town of Grünwald, outside of Munich.
Dermapharm´s unique integrated business model comprises in-house development, along with in-house production and distribution of its portfolio by a medical and pharmaceutical sales force. In addition to Germany, the company’s core markets include other European countries, including the UK, Italy, Spain, Austria and Switzerland.
Dermapharm has optimized, and continues to optimize, its business through external acquisitions in addition to organic growth and is focused on stable expansion in the future. To further ensure the company’s future development Dermapharm’s parent company, Dermapharm Holding SE, has been listed on the regulated market (Prime Standard) of the Frankfurt Stock Exchange since February 2018.
* EU: patent no. 3308752; U.S. no. 16/317,147: patent pending